Sai Life Sciences Limited has informed the Exchange regarding 'Reply to IiAS on recommendation of Postal Ballot Notice (under of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018'.
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sai Life Sciences has formally responded to Institutional Investor Advisory Services (IiAS), which had recommended shareholders vote 'AGAINST' certain resolutions in the company's May 15, 2025 postal ballot. The disputed resolutions cover ratification of the ESOP 2008 and ESOP 2018 employee stock option plans, extension of these plans to subsidiary and group company employees, and the appointment of Sivaramakrishnan Chittor as Whole-Time Director and CFO along with his remuneration. The company contests IiAS's dilution concern, arguing the actual potential dilution is just 1.6% of the expanded capital base (not the headline 6.3%), and clarifies that NRC discretion on exercise price and vesting is permitted under SEBI's SBEB & SE Regulations. On Mr. Chittor's appointment, the company notes no change in compensation structure, no new ESOPs are proposed, and his total remuneration remains capped under Section 197 of the Companies Act. Sai Life has urged IiAS to revise its recommendations and circulate the response to all subscribers.
This is a routine corporate governance communication and does not signal any regulatory action, financial distress, or material event. For shareholders, it means the postal ballot resolutions on ESOPs and the CFO's appointment may face opposing recommendations from a proxy advisor, which could influence institutional voting, but the company maintains the resolutions are compliant and in shareholders' best interest.